EVER FORTUNE.AI CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.6 TWD | +2.88% |
|
+2.51% | -11.30% |
| May. 24 | Ever Fortune.AI Co., Ltd. Announces Board Changes | CI |
| May. 24 | Ever Fortune.AI Co., Ltd. Announces Cash Dividend for the Year 2023 Payable on June 28, 2024 | CI |
| Sales 2022 | 53.9M 1.66M | Sales 2023 | 93.98M 2.9M | Capitalization | 9.38B 289M |
|---|---|---|---|---|---|
| Net income 2022 | 136M 4.2M | Net income 2023 | -42M -1.3M | EV / Sales 2022 | 94.5 x |
| Net cash position 2022 | 1.2B 37.03M | Net cash position 2023 | 1.41B 43.47M | EV / Sales 2023 | 84.8 x |
| P/E ratio 2022 |
46.1
x | P/E ratio 2023 |
-219
x | Employees | - |
| Yield 2022 |
2.82% | Yield 2023 |
-
| Free-Float | 57.33% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.88% | ||
| 1 week | +2.51% | ||
| Current month | +2.88% | ||
| 1 month | +1.06% | ||
| 3 months | -0.93% | ||
| 6 months | -15.67% | ||
| Current year | -11.30% |
1 week
83.00
87.90
1 month
82.6090.20
Current year
82.6097.70
1 year
82.60148.50
3 years
43.80230.00
5 years
43.80230.00
10 years
43.80230.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Cheng Li
CEO | Chief Executive Officer | - | 23-03-22 |
Yung Chun Liang
DFI | Director of Finance/CFO | - | 21-03-07 |
Ming Feng Chen
CHM | Chairman | - | 20-01-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Su Chi Wang
BRD | Director/Board Member | - | 19-06-05 |
Wen Heng Cho
BRD | Director/Board Member | - | - |
Chia Chi Lin
BRD | Director/Board Member | - | 19-06-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 85.6 | +2.88% | 789,756 |
| 24-05-31 | 83.2 | +0.24% | 135,214 |
| 24-05-30 | 83 | -0.72% | 161,196 |
| 24-05-29 | 83.6 | -0.71% | 272,576 |
| 24-05-28 | 84.2 | +0.84% | 200,567 |
End-of-day quote Taipei Exchange, June 02, 2024
More quotes
Ever Fortune. AI Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of medical artificial intelligence software related products. The Company mainly provides medical big data and cloud biomedical platform, medical artificial intelligence (AI) technology solutions. The Company provides medical artificial intelligence data, analysis technology and services, and customized medical AI technology solutions. The Company's products include radiographic bone age-assisted interpretation and height prediction system, ultrasound breast tumor auxiliary classification system, computer tomography liver cancer metastasis risk management system, liver fibrosis evaluation system, and irregular cardiac fibrillation interpretation.
Sector
IT Services & Consulting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
85.6
TWD
Average target price
130
TWD
Spread / Average Target
+51.87%
| 1st Jan change | Capi. | |
|---|---|---|
| -11.30% | 257M | |
| -19.71% | 177B | |
| -3.58% | 161B | |
| +1.06% | 152B | |
| +4.74% | 99.88B | |
| +10.03% | 81.66B | |
| +20.90% | 74.66B | |
| -10.23% | 70.05B | |
| -31.19% | 45.84B | |
| -11.56% | 42.83B |
- Stock Market
- Equities
- 6841 Stock
